Now accepting waitlist applications

Personalized mRNA Hope
for Your Dog's Cancer Fight

RosieVaccine is a bioinformatics design service for veterinary oncologists. We take a tumor biopsy and a matched blood sample and return a codon-optimized mRNA blueprint targeting your dog's specific neoantigens.

Join the Waitlist →

Experimental service · Veterinarian oversight required

Why this exists

Dogs get cancer at roughly the same rate as humans.
They get a fraction of the immunotherapy.

Personalized neoantigen vaccines are the most significant development in oncology in a decade. In humans, Moderna and Merck's mRNA-4157, combined with Keytruda, lowered the risk of melanoma recurrence or death by about 44% in a randomised phase 2b trial. BioNTech's autogene cevumeran is producing durable T-cell responses in pancreatic cancer trials. Dozens of late-stage human programs are running.

In veterinary oncology, the equivalent therapies are mostly autologous tumor lysates, shared tumor-associated antigens, or dendritic cell preparations. None of them are personalized to a specific patient's mutations. None of them are mRNA. None of them use the bioinformatics that's now standard practice on the human side.

The bioinformatics that designs a personalized human cancer vaccine is essentially the same bioinformatics that designs one for a dog. The species reference is different, the MHC alleles are different, the codon table is different, but the pipeline shape is identical. The science to close that gap has existed for several years. What's been missing is someone who would build the pipeline.

~6M

Canine cancer diagnoses per year in the United States.

Source: Veterinary Cancer Society

44%

Lower risk of melanoma recurrence or death, mRNA-4157 + Keytruda (phase 2b).

Source: KEYNOTE-942, The Lancet (2024)

0

Personalized neoantigen mRNA vaccines currently available in veterinary oncology.

As of 2026

The story that inspired us

Paul Conyngham proved it on his rescue dog Rosie.
We're making it accessible to every dog with cancer.

In 2025, Australian data analyst Paul Conyngham did something canine oncology hadn't seen before. He treated his rescue dog Rosie's aggressive mast cell tumours as a data-science problem: he sequenced her tumor and matched healthy DNA, ran open-source bioinformatics to identify the cancer-driving mutations, and designed a personalized mRNA vaccine targeting them. The vaccine was synthesized at UNSW's RNA Institute and administered by a licensed veterinary oncologist. Rosie's tumours shrank by approximately 75% in the months that followed.

Rosie's case is a single n=1, documented in the open. It is not a clinical trial, and it does not establish efficacy. What it does establish is that the workflow runs end-to-end on a real patient: paired sequencing, neoantigen prediction, canine codon-optimized mRNA, vet-administered. The science to bring personalized mRNA cancer vaccines to dogs has existed for several years. What was missing was someone to turn it into a reproducible service.

That's what we built. RosieVaccine is a US-based team of scientists, engineers, and clinicians, working alongside the veterinary oncologists who'll bring these vaccines to their patients.

Built by

Scientists, engineers, and clinicians.

Scientists

Bioinformatics · neoantigen prediction · canine immunology

Engineers

Pipeline · clinical decision support · mobile outcomes app

Clinicians

Veterinary oncology guidance · pilot case review

United States · Independent · Closed beta

Paul's story, covered by

Fortune Newsweek UNSW News The Conversation Reason Cancer Health

The process

Three stages, from sample to outcome.

A clean workflow built around your clinic. Here's the short version. Click any stage for the full detail.

01

Sample to lab

A prepaid kit arrives at your clinic. You collect a tumor sample and a matched blood sample during the procedure you were already doing, and ship it back the same day.

See stage 1 →

02

Lab to vaccine

Our pipeline does the heavy analysis on canine-specific biology. You review the recommendations and make the final call. The vaccine is then manufactured by our single CDMO partner.

See stage 2 →

03

Vaccine to outcome

The vaccine ships cold-chain to your clinic with a labeled dosing schedule. Follow-up moves to the owner's phone, and structured outcomes feed back into your dashboard.

See stage 3 →
See the full workflow →

Partnership

We work case-by-case, alongside your clinical judgment.

We're currently in closed beta and accepting a small number of pilot cases per quarter. If you have a patient who has exhausted standard of care, or one you believe is a candidate for adjuvant personalized immunotherapy after surgical resection, we'd like to hear from you. We're particularly interested in:

  • Patients who have exhausted standard of care and where the owner is seeking experimental options under appropriate informed consent
  • Adjuvant cases following surgical resection where personalized immunotherapy could plausibly address residual disease
  • Tumour types with a reasonable somatic mutation burden: mast cell tumours, melanoma, osteosarcoma, hemangiosarcoma, and lymphomas have been our primary focus
  • Clinicians with access to, or willingness to engage with, an ethics framework appropriate to their jurisdiction

Each pilot case is reviewed individually by our scientific and clinical advisors before we agree to proceed. We work within your existing clinical decision-making, and we'll turn down cases where we don't believe the science supports a reasonable chance of benefit, or where the clinical context isn't right.

Request a pilot case →

Select Veterinarian / Oncologist in the form below and tell us about your patient.

For pet owners

Talk to your veterinary oncologist first.

If you're a pet owner who's found this site because your dog has cancer, we know how much that hurts. The right way to access a service like ours is through your veterinary oncologist, not around them. If your oncologist would like to evaluate whether a personalized mRNA approach makes sense for your dog, we're happy to talk with them.

To be notified when we expand access, join the waitlist below. We won't email you with marketing, only substantive updates.

Please don't include sensitive personal or human medical information.

We respect your privacy. No spam, ever.

Thanks, we got it.

We respond within two business days. If you're a veterinary oncologist with a specific patient in mind, we'll get back to you with next steps.

From our blog

Reading for pet owners and veterinarians.

Explainers, treatment guides, and our notes on what the field is learning.

Treatment guide · 12 min read · June 2026

Melanoma in Dogs: A 2026 Guide to Treatment Options.

A melanoma in the mouth behaves nothing like one on the skin. The types, diagnosis and staging, surgery, radiation, the ONCEPT vaccine, and where personalized mRNA cancer vaccines fit in.

Read the guide →

Treatment guide · 11 min read · June 2026

Mast Cell Tumours in Dogs: A 2026 Guide to Treatment Options.

Mast cell tumours are the most common skin cancer in dogs, about one in five canine skin tumours. Standard of care is well established, but the field is changing fast. A walkthrough of surgery, chemotherapy, targeted therapy, and where personalized mRNA cancer vaccines fit in.

Read the guide →
All posts →

FAQ

Questions pet owners and veterinarians ask.

If your question isn't here, get in touch through the waitlist form above.

Is there an mRNA cancer vaccine for dogs?

Personalized mRNA cancer vaccines for dogs are an emerging modality. The same neoantigen-targeting approach now in late-stage human trials, including Moderna and Merck's mRNA-4157 in melanoma and BioNTech's autogene cevumeran in pancreatic cancer, can be adapted for canine biology. RosieVaccine is currently in closed beta with a small number of pilot cases per quarter; we are not yet a generally available product.

How much does a personalized mRNA cancer vaccine for a dog cost?

During closed beta, pricing is handled case-by-case rather than published as a rate. Pilot cases are priced at cost rather than at a margin. The goal of this phase is to learn carefully from each case, not to scale revenue. The line items typically include tumor and germline sequencing, our design work, and mRNA synthesis through our CDMO partner. We quote each case after reviewing it.

What tumour types are good candidates for a personalized mRNA cancer vaccine?

Tumours with a reasonable somatic mutation burden, meaning the cancer carries enough unique mutations to give the immune system clear targets, work best. Our primary focus has been mast cell tumours, melanoma, osteosarcoma, hemangiosarcoma, and lymphomas. We discuss case fit individually with the veterinary oncologist before accepting a pilot.

How should my dog's tumor sample be preserved for a vaccine?

This is the most common first question, and the single most important thing is to act before the sample is discarded. The gold standard is fresh-frozen tissue: a piece of the tumor snap-frozen in liquid nitrogen within about 30 minutes of removal, cut into small (3–5 mm) pieces, split across several vials, and never allowed to thaw. In practice, most tumors are already fixed in formalin and embedded in paraffin (an FFPE block) by the pathology lab, and that is workable too. FFPE is used routinely for tumor DNA sequencing, though it yields lower-quality DNA than fresh-frozen. We also need a matched normal sample, a simple blood draw in an EDTA tube, to tell your dog's inherited DNA apart from the cancer's mutations. If surgery has already happened, the time-sensitive step is to ask your vet to have the histopathology lab place a hold on whatever tumor material remains (block and/or slides), because labs routinely discard specimens after a set window. Always let your surgeon and oncologist lead the clinical side. Read our full guide to preserving a tumor sample →

How is a personalized cancer vaccine different from chemotherapy?

Chemotherapy attacks the tumor directly, often with significant side effects on healthy cells. A personalized cancer vaccine instead trains the dog's own immune system to recognize the specific mutations that distinguish the tumor from healthy tissue. The two approaches can be complementary, since many human protocols use both, and a personalized vaccine is typically offered adjuvant to standard of care, not as a replacement for it.

Who actually administers the vaccine?

Your veterinary oncologist, under their existing clinical judgment and ethics framework. RosieVaccine is a bioinformatics design service. We do not manufacture vaccines, treat patients, or practice veterinary medicine. The synthesized vaccine ships back to your clinic in a cold-chain shipment with a printed dosing schedule; administration happens entirely under your oncologist's care.

Is RosieVaccine FDA-approved?

Veterinary biologics in the United States are regulated by the USDA, not the FDA. RosieVaccine is operating in closed beta, with pilot cases administered by licensed veterinary oncologists under their clinical and ethical frameworks. We do not currently hold a USDA Autologous Prescription Product (APP) license; we work within the regulatory framework available to veterinary oncologists today.

How does a pet owner enrol a dog in the pilot?

Through your veterinary oncologist, not directly. If your oncologist would like to evaluate whether a personalized mRNA approach makes sense for your dog, they can request a pilot case through the waitlist form on this page. Each case is reviewed individually by our scientific and clinical advisors before we agree to proceed.

Important Disclaimer

RosieVaccine.com is an experimental AI-assisted bioinformatics design service. We do not manufacture vaccines, administer treatments, or practice veterinary medicine. The mRNA blueprints we generate are computational outputs intended for review and use only under the direct supervision of a licensed veterinary oncologist. This service does not guarantee any clinical outcome, and individual results will vary. Personalized cancer vaccine design is an emerging field. While Paul and Rosie's story is real and documented, it represents a single case and should not be interpreted as a promise of similar results. Always consult your veterinarian before pursuing any cancer treatment for your pet.